COMMUNIQUÉS West-GlobeNewswire

Dermavant Sciences Announces Appointment of Cyril Allouche as Chief Financial Officer and Provides Recent Corporate Update
27/03/2019
Mr. Allouche has over 20 years of combined experience in finance leadership, audit, and advisory roles, most recently serving as Principal Accounting Officer, Head of Finance, and Corporate Controller at Revance [...]
Supreme Cannabis Scales Up Production & Into Higher Margin Product Lines -- CFN Media
27/03/2019
SEATTLE, March 27, 2019 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry announces publication of an article featuring [...]
Final Results
27/03/2019
Summit Therapeutics plc (‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2019 and Operational Progress Focus on Improving [...]
CB2 Insights Signs Agreement with Premier Health to Integrate Medical Cannabis Clinical Decision Support Tool
27/03/2019
First-of-its-Kind EMR Platform Integration to Provide Tool for Nearly 5,000 Physicians and Healthcare Practitioners to Qualify and Prescribe Medical Cannabis TORONTO, March 27, 2019 (GLOBE NEWSWIRE) -- CB2 Insights (CSE [...]
Aclaris Therapeutics to Attend Upcoming Investor Conference
27/03/2019
WAYNE, Pa., March 27, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on dermatological and immuno-inflammatory diseases, today announced that [...]
Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Major Depressive Disorder
27/03/2019
Designation offers potential for expedited development and review NEW YORK, March 27, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel [...]
CFN Media Interviews High Hampton’s CEO to Discuss 2019 Catalysts
27/03/2019
SEATTLE, March 27, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry announces publication of an [...]
Eyenovia Reports Fourth Quarter and Full Year 2018 Financial Results
27/03/2019
NEW YORK, March 27, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print [...]
Tetra Bio-Pharma to File PPP001 With the European Medicines Agency
27/03/2019
OTTAWA, March 27, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (" Tetra " or the " Company ") (TSX-V: TBP) (OTCQB: TBPMF) , today announced it is ready to submit its PPP001 cannabinoid-derived drug as a herbal [...]
Achillion Announces Completion of Enrollment in Phase 2 PNH Combination Trial
27/03/2019
- Completed enrollment in ACH-4471 Phase 2 PNH trial in combination with eculizumab - - Interim data to be released in May 2019 - - Targeting FDA end-of-Phase 2 meeting in second half of 2019 - BLUE BELL, Pa., March 27 [...]
Vital Therapies Reminds Stockholders to Vote For the Proposed Business Combination With Immunic AG
27/03/2019
Of the Votes Received to Date, More than 98% are Voting in Favor of the Business Combination More Votes are Needed to Reach 50% of the Outstanding Shares Required for the Business Combination to Go Forward Every Vote is [...]
Genmab Announces European Regulatory Submission for Daratumumab in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma
27/03/2019
Company Announcement Type II variation application submitted to the EMA for daratumumab in combination with bortezomib, thalidomide and dexamethasone as treatment for newly diagnosed patients with multiple myeloma who [...]
Genfit: GENFIT ANNOUNCES TRADING HALT OF ITS SHARES AND OF ITS OCEANES ON EURONEXT PARIS AND EURONEXT ACCESS
27/03/2019
FOR IMMEDIATE RELEASE GENFIT ANNOUNCES TRADING HALT OF ITS SHARES AND OF ITS OCEANES ON EURONEXT PARIS AND EURONEXT ACCESS Lille (France), Cambridge (Massachusetts, United States), March 27, 2019 - 9.00 am CET – GENFIT [...]
Genfit: GENFIT ANNONCE LA SUSPENSION DU COURS DE SES ACTIONS ET DE SES OCEANES SUR EURONEXT PARIS ET EURONEXT ACCESS
27/03/2019
CE COMMUNIQUÉ N’EST PAS DESTINÉ A ÊTRE PUBLIÉ, DISTRIBUÉ OU DIFFUSÉ, DIRECTEMENT OU INDIRECTEMENT, AUX ÉTATS-UNIS D’AMÉRIQUE NI À DES RESSORTISSANTS AMÉRICAINS (« U.S. PERSONS »), POUR LEUR BÉNÉFICE OU POUR LEUR COMPTE [...]
Aino Health AB (publ): Aino Health and Veritas Pension Insurance will launch Work Ability Support Service Center
27/03/2019
27 th of March, 2019 Aino Health together with Veritas Pension Insurance co-created and will launch a unique work ability support service for Veritas' customers. The service will be operational in Q2 2019. In the first [...]
Genfit: GENFIT Announces Pricing of Global Offering and Approval to List on Nasdaq Global Select Market
27/03/2019
FOR IMMEDIATE RELEASE GENFIT Announces Pricing of Global Offering and Approval to List on Nasdaq Global Select Market Lille (France), Cambridge (Massachusetts, United States), March 27, 2019 – GENFIT SA (Euronext: GNFT [...]
Genfit: GENFIT annonce le succès de son introduction en bourse sur le Nasdaq dans le cadre d’une offre globale d’American Depositary Shares aux États-Unis et d’un placement privé d’actions
27/03/2019
CE COMMUNIQUÉ N’EST PAS DESTINÉ A ÊTRE PUBLIÉ, DISTRIBUÉ OU DIFFUSÉ, DIRECTEMENT OU INDIRECTEMENT, AUX ÉTATS-UNIS D’AMÉRIQUE NI À DES RESSORTISSANTS AMÉRICAINS (« U.S. PERSONS »), POUR LEUR BÉNÉFICE OU POUR LEUR COMPTE [...]
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
27/03/2019
Mayzent ® (siponimod) is the first and only treatment specifically approved for patients with active secondary progressive multiple sclerosis (SPMS) in over 15 years[1] Up to 80% of patients with relapsing remitting MS [...]
MyoKardia Announces Pricing of Public Offering of Common Stock
26/03/2019
SOUTH SAN FRANCISCO, Calif., March 26, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious [...]

Pages